Clinical trials: Prostatic Adenocarcinoma
Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
This randomized phase III trial studies two different schedules of zoledronic acid to compare how well they work in reducing bone-related complications in patients with breast cancer, prostate cancer, or multiple myeloma that has…
- Conditions
- Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone
- Trial name
- NCT00869206
- Testing
- zoledronic acid
- Where
- 504 sites in United States, Puerto Rico
- Volunteers
- 1,822 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have prostate…
- Trial name
- NCT00016393
- Testing
- ixabepilone
- Where
- 28 sites in United States
- Sponsor
- SWOG Cancer Research Network
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer
This phase II trial is studying how well vaccine therapy works in treating patients with recurrent prostate cancer. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells
- Trial name
- NCT00109811
- Testing
- PSA:154-163(155L) peptide vaccine, incomplete Freund's adjuvant, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral…
- Conditions
- Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma)
- Trial name
- MODeFIRe-1 (NCT07745361)
- Testing
- Oral MRT-2359, Apalutamide
- Where
- 14 sites in United States
- Volunteers
- 25 people
- Sponsor
- Monte Rosa Therapeutics, Inc
Prostate Cancer
Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy
RATIONALE: Celecoxib may stop the growth of cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth.
- Trial name
- NCT00073970
- Testing
- celecoxib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Prostate Cancer, Prostate Adenocarcinoma
Initial Experience in Brazilian Single Center With High Intensity Focalized Ultrasound (HIFU) Prostate Cancer Therapy: Morbidity, Oncological and Functional Outcomes.
Prostate cancer (PCa) is the most prevalent non cutaneous cancer in occidental countries. In Brazil incidence was about sixty thousand new cases in 2016 and occupied second place as all cancer mortality, just behind lung cancer.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Transrectal High Intensity Focused Ultrasound
- Trial name
- NCT03255135
- Testing
- HIFU
- Where
- Brazil
- Volunteers
- 130 people
- Sponsor
- Hospital de Transplante Doutor Euryclides de Jesus Zerbini
Adenocarcinoma of Prostate
Short-term High Precision Radiotherapy for Early Prostate Cancer With Concomitant Boost on the Dominant Lesion
The present research project aims to improve the current treatment for prostate-confined tumor, evaluating the safety and feasibility of a very short hypofractionated radiotherapy schedule administered with one of the best…
- Trial name
- NCT01913717
- Testing
- External beam radiotherapy
- Where
- Italy
- Volunteers
- 65 people
- Sponsor
- European Institute of Oncology
Prostate Adenocarcinoma
Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer
This pilot partially-randomized phase II trial studies how well Supportive Therapy in Androgen Deprivation (STAND) clinic works in improving health outcomes and managing side effects in patients with prostate cancer.
- Trial name
- NCT02168062
- Testing
- Behavioral Dietary Intervention, Counseling, Educational Intervention
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of California, San Francisco
Pain, Prostate Cancer
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00005960
- Testing
- filgrastim, cyclophosphamide, docetaxel
- Where
- 6 sites in United States
- Sponsor
- Amgen
Prostate Cancer
Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer
The purpose of this study is to see what effects, good and/or bad, proton based radiation combined with low dose chemotherapy and hormonal therapy, has on patients and their cancer.
- Trial name
- PR05 (NCT01040624)
- Testing
- < 15% risk of + LN, > 15% risk of + LN
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Florida
Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer
This phase II trial studies how well focal radiation therapy with stereotactic body radiation therapy (SBRT) or high-dose rate (HDR) brachytherapy works in treating patients with low or intermediate-risk prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8
- Trial name
- NCT04399824
- Testing
- High-Dose Rate Brachytherapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer (Adenocarcinoma)
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
This is a Phase I/II trial evaluating the effectiveness of adding neoadjuvant HDR-B prior to RALP for HR-PCa patients with selective AAB for decipher high risk or pathologically node positive patients.
- Trial name
- NCT07182279
- Testing
- Brachytherapy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- The Methodist Hospital Research Institute
Prostate Cancer
Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving everolimus before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be…
- Trial name
- NCT00526591
- Testing
- Everolimus, conventional surgery
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Jorge A. Garcia, MD
Prostate Cancer
MLN8237 for a Subject With Adenocarcinoma of the Prostate
To allow a patient continued access to MLN8237
- Trial name
- NCT03005262
- Testing
- MLN8237
- Sponsor
- The University of Texas Health Science Center at San Antonio
Prostate Cancer
Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse
RATIONALE: Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving CCI-779 before surgery may shrink the tumor so that it can be removed.
- Trial name
- NCT00071968
- Testing
- temsirolimus, conventional surgery, neoadjuvant therapy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Adenocarcinoma
INSPIRE: INnovative SABR for Prostate Cancer All IREland
This is a Phase II, single arm, multi-centre, prospective clinical trial evaluating next generation Stereotactic Ablative Radiotherapy (SABR) for low, intermediate, and eligible high-risk prostate cancer.
- Trial name
- NCT07552168
- Testing
- Next generation Stereotactic Ablative Radiotherapy (SABR)
- Where
- 4 sites in Ireland, United Kingdom
- Volunteers
- 136 people
- Sponsor
- Cancer Trials Ireland
Prostate Cancer, Neuroendocrine Tumors
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
An open-label, multicenter, Phase 1b/2 study to identify the recommended Phase 2 dose and assess the efficacy and safety of BXCL701 administered orally, as monotherapy and in combination with PEMBRO, in patients with mCRPC.
- Conditions
- Prostate Cancer, Neuroendocrine Tumors, Small Cell Carcinoma
- Trial name
- NCT03910660
- Testing
- BXCL701 plus Pembrolizumab, BXCL701 monotherapy
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 98 people
- Sponsor
- BioXcel Therapeutics Inc
Prostate Cancer (Adenocarcinoma), Renal Cancer
Comparison Between HUGO RAS Robotic Platform and Da Vinci Robotic Platform
The study is designed as a single-center, prospective, interventional, non-pharmacological, randomized, open-label, controlled trial with parallel groups.
- Trial name
- URO-ROBOT-2023 (NCT06844513)
- Testing
- Radical prostatectomy, Partial nephrectomy
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Disease
Osteosclerotic Changes on CT Predict Survival in Prostate Cancer
The study specifically investigated PC patients with bone metastasis and conducted a comprehensive analysis of the correlation between OCs and patient survival outcomes.
- Trial name
- NCT06883474
- Testing
- Osteosclerotic Changes on Computed Tomography
- Volunteers
- 211 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer
Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate
In North America, around a quarter a million men are diagnosed with prostate cancer every year, and about 31,000 patients will die of their disease each year.
- Trial name
- NCT01444820
- Testing
- hypofractionation, conventional
- Where
- 12 sites in Canada
- Volunteers
- 329 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital